The decision is based on positive data from the phase 3 aegean trial. It includes different subtypes like adenocarcinoma and squamous cell carcinoma This article discusses the use of durvalumab, a monoclonal antibody to human immunoglobulin g1, as a novel treatment for unresectable stage iii nsclc.
Japanese - Department of Language & Literature
Each cancer type has unique traits and demands specific care plans
